Dr. Saman Maleki

speaker

104 appearances 1 recordings 1 series first heard Feb 2026 last heard 4 Feb

Dr. Saman Maleki’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

The Last Show with David Cooper · FULL EPISODE: What Kind Of Medication?! - February 3, 2026 · 4 Feb 2026 podcast

That was the initial idea for me to go and talk to my colleagues in the infectious disease department, saying that, can we do this in cancer patients?

And they were like,

Wow.

Nobody has asked us to do this in cancer patients.

What are the results?

Yeah, that's a great question.

So, so far, we have treated across different cancer sites that we've treated patients in different clinical trials.

I can tell you that we've treated over 100 cancer patients.

And what one you may call the biomarker or hint that we have that this works is that the patients who can take this and keep it in their microbiome over time, that means their microbiome becomes like the donor microbiome, they do tend to do better.

In the initial study that we published in Nature Medicine in melanoma patients, that's a deadly form of skin cancer a couple of years ago,

we showed that there are certain characteristics in the patients that we are still studying that actually determines if they can be a host that can keep the donor microbiome.

It's like, if you will, that the kidney transplant is not getting rejected.

So one of them was that if they're alpha diversity, that means the shape of their microbiome was actually more diseased than normal, believe it or not.

And the reason for that, we think, is that when somebody's microbiome is

actually less healthy, it's easier to change it.

So we have good evidence in the CD4 as well, rather than somebody's microbiome who's healthy.

You look pretty healthy, so it might be more difficult to change your microbiome.

Yeah, that's a great question.

And that's something that we are working on right now.

We are building two randomized clinical trials, one in melanoma in 128 patients in Canada.

Showing 81–100 of 104 · page 5 of 6